ArticleFrontiers in oncology2025
Cost-effectiveness of open versus laparoscopic pancreaticoduodenectomy: a retrospective Markov model analysis from China.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Open pancreaticoduodenectomy (OPD) and laparoscopic pancreaticoduodenectomy (LPD) are the two main surgical approaches for treating pancreatic cancer. Objective: To evaluate the cost-effectiveness of OPD and LPD in treating pancreatic ductal adenocarcinoma by establishing a Markov Model. Methods: Patients with pancreatic ductal adenocarcinoma who staged at I-III undergone OPD or LPD were retrospectively included from March 2017 to December 2020. Patients were followed up by telephone until June 2024. A Markov Model was established to simulate disease progression after 120 cycles by including survival data and average hospitalization costs. Results: Two hundred patients were included, 100 for OPD group and the other 100 for LPD group. The results indicated that after 10 years of model operation, the LPD group had an increased cost of 13,175.31 yuan compared to the OPD group, with an incremental effect of 0.063 per quality-adjusted life years (QALY). It also showed that the incremental cost-effectiveness ratio value was ¥205,864.22per QALY, which was less than willing to pay (¥268,074.00). Conclusion: This study is the first to analyze the cost-effectiveness of OPD versus LPD in PDAC. The study indicated that LPD remains an acceptable operation with certain cost-effectiveness for pancreatic cancer patients. However, due to the low survival rates and the fact that LPD is a highly technique-dependent operation for pancreatic cancer, surgeons should keep cautious of the choice between the OPD and LPD based on the patient's expectation and financial situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.